JP2015521041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521041A5 JP2015521041A5 JP2015511948A JP2015511948A JP2015521041A5 JP 2015521041 A5 JP2015521041 A5 JP 2015521041A5 JP 2015511948 A JP2015511948 A JP 2015511948A JP 2015511948 A JP2015511948 A JP 2015511948A JP 2015521041 A5 JP2015521041 A5 JP 2015521041A5
- Authority
- JP
- Japan
- Prior art keywords
- pkn3
- inhibitor
- vegfr1
- suffering
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100006565 FLT1 Human genes 0.000 claims 2
- 101710030892 FLT1 Proteins 0.000 claims 2
- 102100012183 PKN3 Human genes 0.000 claims 2
- 101700083940 PKN3 Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
Claims (1)
- 疾患に罹患している、または疾患に罹患する危険性がある対象の治療方法において使用するためのＰＫＮ３阻害剤であって、前記対象の血液または血漿中のＶＥＧＦ１の力価で表されたＶＥＧＦＲ１またはＶＥＧＦＲ１をコードする核酸の発現レベルが２００ｐｇ／ｍｌ以上である、ＰＫＮ３阻害剤。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12003888.0 | 2012-05-16 | ||
| EP12003888 | 2012-05-16 | ||
| PCT/EP2013/001441 WO2013170960A1 (en) | 2012-05-16 | 2013-05-15 | Use of vegfr1 as a biomarker for pkn3 inhibitor administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015521041A JP2015521041A (ja) | 2015-07-27 |
| JP2015521041A5 true JP2015521041A5 (ja) | 2016-07-07 |
Family
ID=48446240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511948A Pending JP2015521041A (ja) | 2012-05-16 | 2013-05-15 | Ｐｋｎ３阻害剤投与のためのバイオマーカーとしてのｖｅｇｆｒ１の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9133515B2 (ja) |
| EP (1) | EP2849771A1 (ja) |
| JP (1) | JP2015521041A (ja) |
| WO (1) | WO2013170960A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016083623A1 (en) * | 2014-11-28 | 2016-06-02 | Silence Therapeutics Gmbh | Means for the treatment of pre-eclampsia |
| EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
| US20040220128A1 (en) * | 1995-10-26 | 2004-11-04 | Sirna Therapeutics, Inc. | Nucleic acid based modulation of female reproductive diseases and conditions |
| WO1998008856A2 (de) | 1996-08-30 | 1998-03-05 | Fuerste Jens Peter | Spiegelselektion und spiegelevolution von nucleinsäuren |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6958239B2 (en) | 1996-11-21 | 2005-10-25 | Oligos Etc Inc. | Three component chimeric antisense oligonucleotides |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
| SI1536827T1 (sl) | 2002-08-14 | 2009-06-30 | Silence Therapeutics Ag | Uporaba protein-kinaze n beta |
| CA2658550C (en) | 2006-07-21 | 2018-06-19 | Silence Therapeutics Ag | Means for inhibiting the expression of protein kinase 3 |
-
2013
- 2013-05-15 WO PCT/EP2013/001441 patent/WO2013170960A1/en active Application Filing
- 2013-05-15 JP JP2015511948A patent/JP2015521041A/ja active Pending
- 2013-05-15 EP EP13723000.9A patent/EP2849771A1/en not_active Withdrawn
- 2013-05-15 US US13/894,650 patent/US9133515B2/en not_active Expired - Fee Related
-
2015
- 2015-08-28 US US14/838,431 patent/US20150368650A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2020510I1 (lt) | Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui | |
| MX2016002987A (es) | Biomarcadores de expresion de genes con sensibilidad a laquinimod. | |
| JP2015520667A5 (ja) | ||
| SG11201400616YA (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
| ZA201403549B (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| DK3730136T3 (da) | Anvendelse af ferricitrat til behandlingen af patienter med kronisk nyresygdom | |
| WO2012112315A3 (en) | Methods for diagnosis of kawasaki disease | |
| CY2020015I1 (el) | Σικλεσονιδη για τη θεραπεια της νοσου των αεραγωγων σε αλογα | |
| DK2945642T3 (da) | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme | |
| WO2013160315A3 (en) | Genetic predictors of response to treatment with crhr1 antagonists | |
| EP2994134A4 (en) | Methods of administering dantrolene for the acute treatment of cardiac arrhythmias | |
| CL2013002905A1 (es) | Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares. | |
| EA201591513A1 (ru) | Терапевтическое применение антител к vegfr1 (варианты) | |
| JP2015521041A5 (ja) | ||
| IL255243B (en) | Biomarkers to determine clinical response to cellular therapy | |
| SG11201509680TA (en) | Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate. | |
| EA201491455A1 (ru) | ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| BR112017021416A2 (pt) | anticorpos anti-flt-1 no tratamento de displasia broncopulmonar. | |
| EA201692013A1 (ru) | Новое применение n,n-бис-2-меркаптоэтил-изофталамида | |
| EA201590473A1 (ru) | Отамиксабан для применения в лечении острого коронарного синдрома без подъема st у пациентов, которым планируется проведение аортокоронарного шунтирования | |
| TH1401005467B (th) | การใช้อนุพันธ์ไพราโซลในการรักษาการกำเริบแบบเฉียบพลันของโรคปอดอุดกั้นชนิดเรื้อรัง | |
| ICHIE | The Beginning of Music & Acoustical Medicine | |
| JP2015525770A5 (ja) | ||
| CN302082371S (zh) | 离子棒 | |
| CN302362744S (zh) | 注水器 |